首页 > 最新文献

Drug Safety - Case Reports最新文献

英文 中文
Acknowledgement to Referees 致推荐人的确认函
Pub Date : 2019-11-16 DOI: 10.1007/s40800-019-0107-6
{"title":"Acknowledgement to Referees","authors":"","doi":"10.1007/s40800-019-0107-6","DOIUrl":"https://doi.org/10.1007/s40800-019-0107-6","url":null,"abstract":"","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77117813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Kidney Injury Following High-Dose Methotrexate Administration in a Day Care Hospital 日托医院大剂量甲氨蝶呤后急性肾损伤
Pub Date : 2019-11-12 DOI: 10.1007/s40800-019-0106-7
S. Misra, A. Santagostino, G. Dine, Larence Bonhomme Faivre
{"title":"Acute Kidney Injury Following High-Dose Methotrexate Administration in a Day Care Hospital","authors":"S. Misra, A. Santagostino, G. Dine, Larence Bonhomme Faivre","doi":"10.1007/s40800-019-0106-7","DOIUrl":"https://doi.org/10.1007/s40800-019-0106-7","url":null,"abstract":"","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74565678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fournier’s Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report 恩格列净治疗2型糖尿病富尼耶坏疽1例
Pub Date : 2019-10-18 DOI: 10.1007/s40800-019-0105-8
Y. Nagano, Naomi Kashiwagi Yakame, H. Aoki, Tamaki Yamakawa, N. Kondo
{"title":"Fournier’s Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report","authors":"Y. Nagano, Naomi Kashiwagi Yakame, H. Aoki, Tamaki Yamakawa, N. Kondo","doi":"10.1007/s40800-019-0105-8","DOIUrl":"https://doi.org/10.1007/s40800-019-0105-8","url":null,"abstract":"","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74598976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
A Case of Oropharyngeal Angioedema Following Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Mechanical Thrombectomy 静脉注射重组组织纤溶酶原激活剂(rt-PA)和机械取栓术后口咽血管性水肿1例
Pub Date : 2019-10-11 DOI: 10.1007/s40800-019-0104-9
Mohamed Shirazy, A. Chaari, K. Hakim, K. Bousselmi, V. Kauts
{"title":"A Case of Oropharyngeal Angioedema Following Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Mechanical Thrombectomy","authors":"Mohamed Shirazy, A. Chaari, K. Hakim, K. Bousselmi, V. Kauts","doi":"10.1007/s40800-019-0104-9","DOIUrl":"https://doi.org/10.1007/s40800-019-0104-9","url":null,"abstract":"","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83199040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy 特发性膜性肾病患者暴露于钙调磷酸酶抑制剂后急性肾损伤
Pub Date : 2019-10-05 DOI: 10.1007/s40800-019-0103-x
Maciej Goździk, Agnieszka Płuciennik, Anna Zawiasa-Bryszewska, Maja Nowicka, Z. Nowicka, M. Wagrowska-Danilewicz, I. Kurnatowska
{"title":"Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy","authors":"Maciej Goździk, Agnieszka Płuciennik, Anna Zawiasa-Bryszewska, Maja Nowicka, Z. Nowicka, M. Wagrowska-Danilewicz, I. Kurnatowska","doi":"10.1007/s40800-019-0103-x","DOIUrl":"https://doi.org/10.1007/s40800-019-0103-x","url":null,"abstract":"","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75759840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Allopurinol-Induced Toxic Epidermal Necrolysis 别嘌呤醇诱导的中毒性表皮坏死松解
Pub Date : 2019-09-23 DOI: 10.1007/s40800-019-0101-z
Ignacio Buenrostro-Rubio, J. A. Silva-Villaseñor, Avi William Hatami-Blechner, Juan J Salazar-Del Valle, N. A. Vázquez-Cárdenas, L. Bustamante-Montes, Rafael González-Álvarez
{"title":"Allopurinol-Induced Toxic Epidermal Necrolysis","authors":"Ignacio Buenrostro-Rubio, J. A. Silva-Villaseñor, Avi William Hatami-Blechner, Juan J Salazar-Del Valle, N. A. Vázquez-Cárdenas, L. Bustamante-Montes, Rafael González-Álvarez","doi":"10.1007/s40800-019-0101-z","DOIUrl":"https://doi.org/10.1007/s40800-019-0101-z","url":null,"abstract":"","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86408165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Isoniazid-Induced Systemic Lupus Erythematosus: A Case Report. 异烟肼诱发的系统性红斑狼疮:病例报告
Pub Date : 2019-09-20 DOI: 10.1007/s40800-019-0102-y
Jitendra H Vaghela, Yogesh Solanki, Krishna Lakhani, Bhargav Purohit

Systemic lupus erythematosus (SLE) can be induced by various medications, such as hydralazine, procainamide, isoniazid, methyldopa, chlorpromazine, quinidine, and minocycline. A patient was admitted complaining of fever with chills and rigor. After being diagnosed with tuberculous meningitis, the patient was given antituberculosis treatment. As the patient did not improve, detailed investigations were conducted, and elevated antinuclear antibody levels were found. The consulting physician diagnosed that the patient was suffering from SLE. As isoniazid is associated with an increased risk of developing SLE, it was suspected as the culprit drug. After withdrawing isoniazid from the antituberculosis treatment regimen, the patient improved and was discharged. Based on the WHO-UMC and Naranjo's causality assessment criteria, an association between the reaction and isoniazid was deemed probable. The reaction was moderately severe (level 4b) according to the modified Hartwig and Siegel scale.

系统性红斑狼疮(SLE)可由多种药物诱发,如肼屈嗪、普鲁卡因胺、异烟肼、甲基多巴、氯丙嗪、奎尼丁和米诺环素。一名患者入院时主诉发热、寒战和全身僵硬。在确诊为结核性脑膜炎后,患者接受了抗结核治疗。由于患者病情未见好转,医生对其进行了详细检查,发现抗核抗体水平升高。会诊医生诊断患者患有系统性红斑狼疮。由于异烟肼会增加患系统性红斑狼疮的风险,因此被怀疑是罪魁祸首。从抗结核治疗方案中撤除异烟肼后,患者病情好转并出院。根据 WHO-UMC 和 Naranjo 的因果关系评估标准,该反应很可能与异烟肼有关。根据修改后的哈特维格和西格尔量表,该反应为中度严重(4b 级)。
{"title":"Isoniazid-Induced Systemic Lupus Erythematosus: A Case Report.","authors":"Jitendra H Vaghela, Yogesh Solanki, Krishna Lakhani, Bhargav Purohit","doi":"10.1007/s40800-019-0102-y","DOIUrl":"10.1007/s40800-019-0102-y","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) can be induced by various medications, such as hydralazine, procainamide, isoniazid, methyldopa, chlorpromazine, quinidine, and minocycline. A patient was admitted complaining of fever with chills and rigor. After being diagnosed with tuberculous meningitis, the patient was given antituberculosis treatment. As the patient did not improve, detailed investigations were conducted, and elevated antinuclear antibody levels were found. The consulting physician diagnosed that the patient was suffering from SLE. As isoniazid is associated with an increased risk of developing SLE, it was suspected as the culprit drug. After withdrawing isoniazid from the antituberculosis treatment regimen, the patient improved and was discharged. Based on the WHO-UMC and Naranjo's causality assessment criteria, an association between the reaction and isoniazid was deemed probable. The reaction was moderately severe (level 4b) according to the modified Hartwig and Siegel scale.</p>","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74237235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report. 致命的维生素k依赖性凝血病与头孢哌酮/舒巴坦:1例报告。
Pub Date : 2019-06-14 DOI: 10.1007/s40800-019-0100-0
Huan-Rong Hu

This case report describes a suspected and fatal adverse reaction involving vitamin K-dependent coagulopathy that might be associated with cefoperazone/sulbactam (CPZ/SAM), a combined antimicrobial formulation. We reported a patient diagnosed with acute cerebral infarction and secondary pulmonary infection who was treated with an intravenous infusion of CPZ/SAM at 3 g twice daily. After receiving treatment with CPZ/SAM, the patient developed a fatal adverse reaction of CPZ-induced hemorrhage. The Naranjo assessment score in this report was 5, suggesting that the patient's coagulation function disorder was potentially associated with the use of CPZ/SAM. To prevent vitamin K-dependent coagulopathy caused by CPZ/SAM, it is suggested to avoid cephalosporins in patients with a high risk of bleeding unless the need for cephalosporins is compelling.

本病例报告描述了一个疑似和致命的不良反应,涉及维生素k依赖性凝血功能障碍,可能与头孢哌酮/舒巴坦(CPZ/SAM),一种联合抗菌制剂有关。我们报告了一位诊断为急性脑梗死和继发性肺部感染的患者,他接受了CPZ/SAM静脉滴注,每次3g,每天两次。在接受CPZ/SAM治疗后,患者发生了CPZ致出血的致命不良反应。本报告的Naranjo评分为5分,提示患者凝血功能障碍可能与CPZ/SAM的使用有关。为了预防由CPZ/SAM引起的维生素k依赖性凝血功能障碍,建议出血风险高的患者避免使用头孢菌素,除非有必要使用头孢菌素。
{"title":"Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report.","authors":"Huan-Rong Hu","doi":"10.1007/s40800-019-0100-0","DOIUrl":"https://doi.org/10.1007/s40800-019-0100-0","url":null,"abstract":"<p><p>This case report describes a suspected and fatal adverse reaction involving vitamin K-dependent coagulopathy that might be associated with cefoperazone/sulbactam (CPZ/SAM), a combined antimicrobial formulation. We reported a patient diagnosed with acute cerebral infarction and secondary pulmonary infection who was treated with an intravenous infusion of CPZ/SAM at 3 g twice daily. After receiving treatment with CPZ/SAM, the patient developed a fatal adverse reaction of CPZ-induced hemorrhage. The Naranjo assessment score in this report was 5, suggesting that the patient's coagulation function disorder was potentially associated with the use of CPZ/SAM. To prevent vitamin K-dependent coagulopathy caused by CPZ/SAM, it is suggested to avoid cephalosporins in patients with a high risk of bleeding unless the need for cephalosporins is compelling.</p>","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40800-019-0100-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37330718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Gastroschisis Following Treatment with High-Dose Methimazole in Pregnancy: A Case Report. 妊娠期大剂量甲巯咪唑治疗胃裂1例。
Pub Date : 2019-05-23 DOI: 10.1007/s40800-019-0099-2
Dyah Purnamasari, Susie Setyowati, Em Yunir, Anandhara Indriani Khumaedi, Dante Saksono Harbuwono

Hyperthyroidism in pregnancy is associated with a increased incidence of low birth weight, preterm birth and admission to the neonatal intensive care unit. However, available treatment options are limited. In this report, we present a case of fetal gastroschisis with a history of intrauterine exposure to methimazole. A 37-year-old woman was diagnosed with Grave's disease 3 years before her pregnancy. She had a poor response to propylthiouracil and required high-dose methimazole before her pregnancy. During the first trimester, she received methimazole 120 mg/day. After her 12th week of pregnancy, she received block-and-replace therapy (levothyroxine [LT4] 50 µg/day) because of the risk of hypothyroidism, and the dose of methimazole was downtitrated to 60 mg/day. Fetal ultrasonography showed fetal growth retardation and gastroschisis at gestational week 33. The relationship between the very high doses of methimazole in the first trimester of pregnancy and the incidence of gastroschisis in this patient was not fully understood because evidence of a relationship between the use of antithyroid drugs in the first trimester and congenital abnormalities in the fetus is lacking. Furthermore block-and-replace therapy is not recommended in pregnancy because it requires a higher dose of methimazole. We recommend preconception counseling and early screening of thyroid function. The counseling should include the best timeline for pregnancy and a discussion of the risks and benefits of hyperthyroidism treatment options.

妊娠期甲状腺功能亢进与低出生体重、早产和新生儿重症监护病房的发生率增加有关。然而,可用的治疗方案是有限的。在这个报告中,我们提出了一个病例胎儿胃裂与子宫内暴露于甲巯咪唑的历史。一名37岁妇女在怀孕前3年被诊断患有格雷夫氏病。她对丙硫脲嘧啶反应不佳,在怀孕前需要大剂量的甲巯咪唑。妊娠早期给予甲巯咪唑120毫克/天。妊娠第12周后,由于存在甲状腺功能减退的风险,患者接受阻断替代治疗(左旋甲状腺素[LT4] 50µg/d),甲巯咪唑剂量降至60 mg/d。孕33周胎儿超声检查显示胎儿发育迟缓,胃裂。由于缺乏妊娠早期使用抗甲状腺药物与胎儿先天性异常之间关系的证据,因此在妊娠早期使用高剂量甲巯咪唑与该患者胃裂发生率之间的关系尚不完全清楚。此外,不建议在怀孕期间使用阻断替代疗法,因为它需要更高剂量的甲巯咪唑。我们建议孕前咨询和甲状腺功能早期筛查。咨询应包括怀孕的最佳时间表和讨论甲状腺机能亢进治疗方案的风险和益处。
{"title":"Gastroschisis Following Treatment with High-Dose Methimazole in Pregnancy: A Case Report.","authors":"Dyah Purnamasari,&nbsp;Susie Setyowati,&nbsp;Em Yunir,&nbsp;Anandhara Indriani Khumaedi,&nbsp;Dante Saksono Harbuwono","doi":"10.1007/s40800-019-0099-2","DOIUrl":"https://doi.org/10.1007/s40800-019-0099-2","url":null,"abstract":"<p><p>Hyperthyroidism in pregnancy is associated with a increased incidence of low birth weight, preterm birth and admission to the neonatal intensive care unit. However, available treatment options are limited. In this report, we present a case of fetal gastroschisis with a history of intrauterine exposure to methimazole. A 37-year-old woman was diagnosed with Grave's disease 3 years before her pregnancy. She had a poor response to propylthiouracil and required high-dose methimazole before her pregnancy. During the first trimester, she received methimazole 120 mg/day. After her 12th week of pregnancy, she received block-and-replace therapy (levothyroxine [LT4] 50 µg/day) because of the risk of hypothyroidism, and the dose of methimazole was downtitrated to 60 mg/day. Fetal ultrasonography showed fetal growth retardation and gastroschisis at gestational week 33. The relationship between the very high doses of methimazole in the first trimester of pregnancy and the incidence of gastroschisis in this patient was not fully understood because evidence of a relationship between the use of antithyroid drugs in the first trimester and congenital abnormalities in the fetus is lacking. Furthermore block-and-replace therapy is not recommended in pregnancy because it requires a higher dose of methimazole. We recommend preconception counseling and early screening of thyroid function. The counseling should include the best timeline for pregnancy and a discussion of the risks and benefits of hyperthyroidism treatment options.</p>","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40800-019-0099-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37273738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Anaphylactic Reaction to Tc-99m Macrosalb. Tc-99m Macrosalb过敏反应。
Pub Date : 2019-03-05 DOI: 10.1007/s40800-019-0097-4
Nanno Schreuder, Quincy de Hoog, Wouter van der Bruggen, Eugène P van Puijenbroek

A 49-year-old woman developed an anaphylactic reaction to Tc-99m macrosalb used for pulmonary scintigraphy. The patient received an intravenous injection of Tc-99m macrosalb 120 MBq, containing macroaggregates of human albumin 0.14 mg. Within 1 min she developed itching all over her body, an itching throat and dyspnoea. This was followed by urticaria and facial oedema. She was diagnosed with an anaphylactic shock. The patient received clemastine and prednisone, and fully recovered after release from the hospital. According to the Naranjo assessment algorithm, the relationship between the allergic reaction and the administration of Tc-99m macrosalb should be considered as 'probable'.

一名49岁女性对用于肺显影的Tc-99m macrosalb出现过敏反应。患者静脉注射Tc-99m macrosalb 120 MBq,含人白蛋白大聚集体0.14 mg。1分钟内,患者出现全身瘙痒、喉咙瘙痒和呼吸困难。随后出现荨麻疹和面部水肿。她被诊断为过敏性休克。患者接受克莱曼汀和强的松治疗,出院后完全康复。根据Naranjo评估算法,过敏反应与给药Tc-99m macrosalb之间的关系应考虑为“可能”。
{"title":"Anaphylactic Reaction to Tc-99m Macrosalb.","authors":"Nanno Schreuder,&nbsp;Quincy de Hoog,&nbsp;Wouter van der Bruggen,&nbsp;Eugène P van Puijenbroek","doi":"10.1007/s40800-019-0097-4","DOIUrl":"https://doi.org/10.1007/s40800-019-0097-4","url":null,"abstract":"<p><p>A 49-year-old woman developed an anaphylactic reaction to Tc-99m macrosalb used for pulmonary scintigraphy. The patient received an intravenous injection of Tc-99m macrosalb 120 MBq, containing macroaggregates of human albumin 0.14 mg. Within 1 min she developed itching all over her body, an itching throat and dyspnoea. This was followed by urticaria and facial oedema. She was diagnosed with an anaphylactic shock. The patient received clemastine and prednisone, and fully recovered after release from the hospital. According to the Naranjo assessment algorithm, the relationship between the allergic reaction and the administration of Tc-99m macrosalb should be considered as 'probable'.</p>","PeriodicalId":11364,"journal":{"name":"Drug Safety - Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40800-019-0097-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37027029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Drug Safety - Case Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1